User: prashantiyengar Topic: IP
Category: drugs :: india
1 new since Sep 16 2014 10:01 IST RSS 2.0
 
1 to 20 of 2,418    
Epirus, Ranbaxy win India approval for arthritis drug copy 16.9.2014 ET: Pharma
Epirus Biopharmaceuticals Inc said India's drug regulator has approved its copy of a top-selling arthritis treatment, paving the way for its launch in the country early next year.
Also found in: [+]
Hepatitis C drug in India to cost 49 lakh less than in US 16.9.2014 TOI: India
Sofosbuvir, the wonder medicine for Hepatitis C that costs $84,000 or Rs 50.4 lakh for a 24-week treatment regimen in the US, will soon be available in India for about $1,800 or roughly Rs 1.1 lakh for the same ...
Also found in: [+]
Hope for 'cheap' hepatitis drug 16.9.2014 Telegraph: Nation
New Delhi, Sept. 15: A US biopharmaceutical company today announced its move to make available a medicine to treat hepatitis C virus infections in India and 90 other developing countries at prices much lower than the treatment-course cost of $84,000 (Rs 51.3 lakh) in the US.
Also found in: [+]
Government to hear out US pharma companies' patent fears 15.9.2014 ET: Pharma
The meeting itself is the fallout of discussions by a committee of secretaries, where it was felt that the government should engage with the companies.
Also found in: [+]
Pfizer, Ranbaxy win dismissal of lawsuit over generic Lipitor 13.9.2014 Sify Finance
Also found in: [+]
US drug patent expiries to benefit Indian pharma industry 10.9.2014 DNA: Popular News
Expiry of drug patents in the US is great news for not only consumers but also the domestic pharmaceutical industry, where generics account for about 75 per cent of total sales, CARE Ratings said in its report released here today. Indian pharmaceutical companies have an opportunity to capitalise on the patent cliff and gain a greater share of the growing generics market. At present, India accounts for nearly 40 per cent of generic drugs, over-the-counter products and 10 per cent of finished dosages used in the US. During 2014-2016, about USD 92 billion worth of patented drugs are expected to go off-patent in the USA as compared to USD 65 billion during 2010-12. Indian companies' share in the US generics market has grown rapidly on the back of aggressive Abbreviated New Drug Application (ANDA) filings, successful pursuit of Para-IV and capitalisation on patent expiries of blockbuster drugs. Under US laws, ANDA filed with a Para-IV certification states that the generic company which is the first-to-file a ...
Also found in: [+]
IPR policy on the cards to protect national interests, says Nirmala Sitharaman 9.9.2014 ET: Policy
The US is threatening to downgrade India’s intellectual property environment in an out-of-cycle review expected shortly.
Also found in: [+]
IPR policy in the works 9.9.2014 Telegraph: Business
New Delhi, Sept. 8: The government plans to come out with a policy on intellectual property rights (IPR) within a few months, with developed nations such as the US and the EU raising concerns over the country's patent rules.
Also found in: [+]
Poly Medicure wins long patent battle against German pharma giant B Braun 8.9.2014 ET: Pharma
This could also bolster its case in some of the other European jurisdictions where it is defending patent infringement suits from the German giant.
Also found in: [+]
Lack of initiative in drug discovery ails India: Dhaval Kumar Patel, Novartis 2.9.2014 ET: Healthcare
One of the biggest concerns about India, according to Patel, is that the country is still way behind others in global advancements made in science.
Also found in: [+]
Japan’s attempt to get in stricter patent protection into free trade agreement raises concern 29.8.2014 India News, Latest News in India, Live News India, India Breaking News - Times of India
There is concern among those working for improving access to medicines regarding Japan’s attempt to get in stricter patent protection laws at the just-concluded round of negotiation of Regional Comprehensive Economic Partnership (RCEP) which includes ...
Also found in: [+]
Pharma-funded patients’ groups pushing industry agenda on biosimilars 29.8.2014 TOI: Home
Patients' groups with significant funding from pharma appear to back the multinational pharmaceutical industry's attempt to block the entry of cheaper copies of biological medicines which could help increase access of these medicines to patients across the world.
Also found in: [+]
Drug makers to inject cash 24.8.2014 Telegraph: Business
Mumbai, Aug. 24: Indian companies may be wary of scrutiny by the US Food and Drug Administration (FDA), but they are also likely to invest more over the next four years to comply with the strict norms set by the regulator.
Also found in: [+]
Vyome Biosciences raises $8 million 18.8.2014 Sify Finance
Vyome Biosciences, a Delhi-based biopharmaceutical company focused on developing dermatology products, has closed a Series-B financing round worth $8 million (Rs 48 crore), led by Sabre Partners.
Also found in: [+]
Lupin local market thrust 17.8.2014 Telegraph: Business
Mumbai, Aug. 17: Lupin, the country's fourth-largest drug maker by sales, expects its domestic business to beat industry growth rates and rise 15-20 per cent annually over the next few years.
Also found in: [+]
Top 20 pharma companies' capex to surge by 40%, says CRISIL 13.8.2014 ET: Pharma
Out of the top 20 pharma companies, capex spending of eight companies, which currently generate a majority of revenues domestically.
Also found in: [+]
Sun Pharma posts Q1 profit on strong U.S. sales 13.8.2014 Sify Finance
MUMBAI (Reuters) - Sun Pharmaceutical Industries Ltd, India's largest drugmaker by market value, reported a better-than-expected first-quarter profit, reflecting higher sales in its largest market,
Also found in: [+]
Live! Nearly 45,000 Indians in Ebola-affected countries: Govt 7.8.2014 Rediff: Top Stories (India)
Also found in: [+]
New Hepatitis-C drug 99% cheaper in India 6.8.2014 India News, Latest News in India, Live News India, India Breaking News - Times of India
US pharma firm Gilead Sciences has offered to introduce Sovaldi, the first breakthrough treatment for hepatitis C virus, in India at nearly 99% discount of the US ...
Also found in: [+]
Time for Indian pharma cos to change strategies 1.8.2014 Rediff: Business
It's time for Indian generic companies to rethink their strategies.
Also found in: [+]
1 to 20 of 2,418